Preston Klassen
President chez REGULUS THERAPEUTICS INC.
Fortune : 770 953 $ au 31/05/2023
Postes actifs de Preston Klassen
Sociétés | Poste | Début | Fin |
---|---|---|---|
REGULUS THERAPEUTICS INC. | Director/Board Member | 23/06/2023 | - |
Chief Tech/Sci/R&D Officer | 22/06/2023 | - | |
President | 22/06/2023 | - |
Historique de carrière de Preston Klassen
Anciens postes connus de Preston Klassen
Sociétés | Poste | Début | Fin |
---|---|---|---|
ZURA BIO LIMITED | Chief Operating Officer | 01/02/2023 | 11/04/2023 |
President | 01/02/2023 | 11/04/2023 | |
METACRINE, INC. | Director/Board Member | 09/06/2020 | 01/02/2023 |
Chief Executive Officer | 09/06/2020 | 01/02/2023 | |
President | 09/06/2020 | 01/02/2023 | |
ARENA PHARMACEUTICALS | Chief Tech/Sci/R&D Officer | 20/03/2017 | 09/06/2020 |
HISTOGEN INC. | Director/Board Member | 07/02/2014 | 01/05/2020 |
Independent Dir/Board Member | 07/02/2014 | 01/05/2020 | |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Chief Tech/Sci/R&D Officer | 01/06/2016 | 01/03/2017 |
President | 01/06/2016 | 01/03/2017 | |
OREXIGEN THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2009 | 27/05/2016 |
AMGEN INC. | Chief Tech/Sci/R&D Officer | 01/06/2002 | 01/11/2009 |
Corporate Officer/Principal | - | - | |
EQUILLIUM, INC. | Director/Board Member | 06/09/2022 | - |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░ ░░░░░░░░░ | ░░░░░░░░░░ | - |
Formation de Preston Klassen
Duke University | Graduate Degree |
Central College | Undergraduate Degree |
University of Nebraska Medical Center | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 14 |
Espagne | 2 |
Canada | 2 |
Opérationnelle
Director/Board Member | 6 |
President | 5 |
Chief Tech/Sci/R&D Officer | 4 |
Sectorielle
Health Technology | 12 |
Consumer Services | 4 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 5 |
---|---|
AMGEN INC. | Health Technology |
REGULUS THERAPEUTICS INC. | Health Technology |
EQUILLIUM, INC. | Health Technology |
ZURA BIO LIMITED | Health Technology |
METACRINE, INC. | Health Technology |
Entreprise privées | 7 |
---|---|
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Conatus Pharmaceuticals, Inc.
Conatus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA. | Health Technology |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Health Technology |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Health Technology |
Sanifit, Inc.
Sanifit, Inc. Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., Sanifit, Inc. is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in San Diego, CA. | Health Technology |
Chinook Therapeutics, Inc. /Old/
Chinook Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Chinook Therapeutics, Inc operates as a biotechnology company, which engages in the development of medicines for kidney diseases. The company is headquartered in Vancouver, Canada. | Commercial Services |
- Bourse
- Insiders
- Preston Klassen
- Expérience